Document:

exv10w2

 

EXHIBIT 10.2

AMENDMENT NO. 1 TO MASTER RESIDUAL LOAN AGREEMENT

     This AMENDMENT NO. 1 TO MASTER RESIDUAL LOAN AGREEMENT (this “Amendment”) is made as of March
15, 2007, to that certain Master Residual Loan Agreement, dated as of April 29, 2005, among Triad
Financial Residual Special Purpose LLC, as borrower (the “Borrower”), The Bank of New York,
successor-in-interest to JPMorgan Chase Bank, National Association, as collection account bank (the
“Collection Account Bank”), and Citigroup Global Markets Realty Corp., as lender (the “Lender”),
(as the same may be amended, supplemented or otherwise modified from time to time in accordance
with the terms thereof, the “Loan Agreement”).

W I T N E S S E T H:

     WHEREAS, the Borrower, the Collection Account Bank and the Lender have entered into the Loan
Agreement; and

     WHEREAS, the Borrower, the Collection Account Bank and the Lender wish to amend the Loan
Agreement as provided herein;

     NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows:

     Section 1.01. Defined Terms. For purposes of this Amendment, unless the context
clearly requires otherwise, all capitalized terms which are used but not otherwise defined herein
shall have the respective meanings ascribed to such terms in the Loan Agreement.

     Section 1.02. Amendment to Definition of “LIBOR”. Section 1 of the Loan Agreement is
hereby amended, effective as of the date hereof, by deleting the following clause from the
definition of “LIBOR”:

(rounded up to the nearest whole multiple of 1/16%).

     Section 1.03. Extension of Term. Pursuant to the last sentence of Section 2(f)(iv) of
the Loan Agreement, the Borrower and Lender hereby agree to renew the commitment of the Lender to
make Loans under the Loan Agreement to April 29, 2009 which shall be the “Renewal Commitment
Termination Date” referred to in clause (c) of the definition thereof in the Loan Agreement.

     Section 1.04. Waiver of Renewal Commitment Fee. In connection with the renewal of the
commitment of the Lender to make Loans under the Loan Agreement pursuant to Section 1.03 of this
Amendment, Lender hereby waives the obligation of the Borrower to pay the Renewal Commitment Fee
specified in clause (iii) of the definition thereof in the Loan Agreement. Such waiver shall apply
only to the renewal specified in Section 1.03 of this Amendment and shall not apply to any future
renewal.

 

 

     Section 1.05. Effect of Amendment. Upon effectiveness of this Amendment, the Loan
Agreement shall be, and be deemed to be, modified and amended in accordance herewith and the
respective rights, limitations, obligations, duties, liabilities and immunities of the Borrower,
the Collection Account Bank, the Lender and each third-party beneficiary of the Loan Agreement
shall hereafter be determined, exercised and enforced subject in all respects to such modification
and amendment, and all the terms and conditions of this Amendment shall be and be deemed to be part
of the terms and conditions of the Loan Agreement for any and all purposes. All other terms and
conditions of the Loan Agreement shall not be modified, amended or waived and shall remain in full
force and effect.

     Section 1.06. Construction of Amendment in Relation to Original Agreement. In case of
any inconsistency between any provisions of this Amendment and any provisions of the Loan Agreement
prior to this Amendment, the provisions of this Amendment shall control.

     Section 1.07. Governing Law. This Amendment shall be governed by, and construed in
accordance with, the laws of the State of New York.

     Section 1.08. Severability of Provisions. If one or more of the provisions of this
Amendment shall be for any reason whatever held invalid or unenforceable, such provision(s) shall
be deemed severable from the remaining covenants, agreements and provisions of this Amendment and
shall in no way affect the validity or enforceability of such remaining provisions or the rights of
any parties hereto or third-party beneficiaries of the Loan Agreement.

     Section 1.09. Binding Effect. The provisions of this Amendment shall be binding upon
and inure to the benefit of the parties hereto and third-party beneficiaries of the Loan Agreement
and their respective successors and permitted assigns.

     Section 1.10. Counterparts. This Amendment may be executed in any number of
counterparts, each of which shall be an original and all of which taken together shall constitute
but one and the same instrument.

2

 

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their
respective officers thereunto duly authorized, as of the day first above written.

	 	 	 	 	 
	 	CITIGROUP GLOBAL MARKETS REALTY CORP.,
Lender

 	 
	 	By:  	/s/ Christopher D'Onofrio
 	 
	 	 	Name:  	Christopher D'Onofrio 	 
	 	 	Title:  	Authorized Signatory 	 
	 
	 	TRIAD FINANCIAL RESIDUAL SPECIAL
PURPOSE LLC,
Seller

 	 
	 	By:  	/s/ Mike L. Wilhelms
 	 
	 	 	Name:  	Mike L. Wilhelms 	 
	 	 	Title:  	Treasurer 	 
	 
	 	THE BANK OF NEW YORK, successor-in-interest
to JPMorgan Chase Bank, National Association,
Collection Account Bank

 	 
	 	By:  	/s/ Janet M. Russo
 	 
	 	 	Name:  	Janet M. Russo 	 
	 	 	Title:  	Assistant Treasurer 	 
	 

	 	 	 	 	 
	 	Acknowledged and Accepted (solely for purposes of
Section 16(c) and Section 16(d) of the Loan Agreement)

TRIAD FINANCIAL CORPORATION

 	 
	 	By:  	/s/ Mike L. Wilhelms
 	 
	 	 	Name:  	Mike L. Wilhelms 	 
	 	 	Title:  	Senior Vice President and Chief Financial Officer 	 
	 

3exv10w36

 

ASSET PURCHASE AGREEMENT

     THIS ASSET PURCHASE AGREEMENT (the “Agreement”) dated March 15, 2007 (the “Effective Date”),
is by and among Uroplasty, Inc., a Minnesota corporation (“Uroplasty”), and CystoMedix, Inc., a
Minnesota corporation (“CystoMedix”).

R E C I T A L S :

     WHEREAS, Uroplasty is a medical device company that develops, manufactures and markets
innovative, proprietary products for the treatment of voiding dysfunctions;

     WHEREAS, CystoMedix is a medical device company that developed products for patients in the
urogynecology and gynecology markets, including neurostimulation devices marketed under the brand
names and trademarks (collectively, the “Trademarks”) URGENT(R), “URGENT-PCTM” and
“URGENT-SQTM” (collectively as now existing or hereafter improved, modified or enhanced, and with
any other CystoMedix products, being referred to hereafter as the “Products”);

     WHEREAS, pursuant to an Exclusive Manufacturing and Distribution Agreement dated April 18,
2005 (the “License Agreement”), Uroplasty has been acting as the exclusive manufacturer and
distributor of the Products in particular territories named therein; and

     WHEREAS, although Uroplasty has an option pursuant to the License Agreement to acquire all of
CystoMedix’s assets, Uroplasty desires to acquire only select intellectual property assets of
CystoMedix on the terms and conditions contained in this Agreement;

     NOW, THEREFORE, IT IS AGREED AS FOLLOWS:

     SECTION 1. DEFINITIONS

     Unless otherwise defined elsewhere in this Agreement, as used in this Agreement and any
exhibits or schedules hereto, the following words and phrases shall have the meanings set forth
below:

     “Act” shall mean the Securities Act of 1933, as amended.

     “Authorization” and “Authorizations” shall have the meanings ascribed to them in Section 5.13
below.

     “Business Day” means any day other than (i) a Saturday or Sunday or (ii) a day on which
banking institutions located in Minneapolis, Minnesota are permitted or required by law, executive
order or governmental decree to remain closed.

 

 

     “Closing” shall mean the consummation of the transactions contemplated herein as described in
Section 4.1 below.

     “Closing Date” shall be the date of the Closing as described in Section 4.1 below.

     “Code” shall mean the Internal Revenue Code of 1986, as amended and interpreted by treasury
regulations.

     “Uroplasty Common Stock” shall mean the Common Stock of Uroplasty, par value $.01 per share.

     “Environmental Law” shall mean any environmental or health and safety-related law, regulation,
rule, ordinance, or by-law at the federal, foreign, state, or local level, whether existing as of
the date hereof, previously enforced or subsequently enacted.

     “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

     “Fraud” shall require a showing of an intent to deceive and, with respect to a claim of
misrepresentation, that the party to be charged had Knowledge of the falsity of the representation
(or acted recklessly in making the representation); and with respect to an omission, that the
party to be charged Knowingly failed to disclose (or acted recklessly in failing to disclose).

     “Hazardous Materials” shall mean and include any hazardous waste, hazardous material,
hazardous substance, petroleum product, oil toxic substance or pollutant as defined in or pursuant
to the Resource Conservation and Recovery Act, as amended, the Comprehensive Environmental
Response, Compensation and Liability Act, as amended, the Hazardous Materials Transportation Act or
any other foreign, federal, state or local law, regulation, ordinance, rule or by-law, whether
existing as of the date hereof, previously enforced or subsequently enacted pertaining to
environmental or health and safety matters.

     “Intellectual Property” shall have the meaning ascribed to it in Section 5.4(a) below.

     “Knowledge” shall mean actual knowledge after reasonable investigation by the individual or
the entity referred to.

     “Person” shall mean an individual, a partnership, a corporation, an association, a joint stock
company, a trust, a joint venture, an unincorporated organization or a governmental entity (or any
department, agency or political subdivision thereof).

     “Purchase Consideration” shall have the meaning ascribed to it in Section 3.1 below.

     “SEC” shall mean the U.S. Securities and Exchange Commission.

-2-

 

     “Taxes” shall mean any federal, state, local or foreign income, gross receipts, license,
payroll, employment, excise, severance, stamp, occupation, premium, windfall profits,
environmental, customs duties, capital stock, franchise, profits, withholding, social security (or
similar), unemployment, disability, real property, personal property, sales, use, transfer,
registration, value-added, alternative or add-on minimum, estimated or other tax of any kind
whatsoever, including any interest, penalty or addition thereto, whether disputed or not.

     “Tax Return” shall mean any return, declaration, report, claim for refund or information
return or statement relating to Taxes, including any schedule or attachment thereto, and including
any amendment thereof.

     SECTION 2. SALE OF ASSETS

     2.1 Sale of Intellectual Property Assets by CystoMedix. Subject to the terms and
conditions set forth in this Agreement, at the Closing, CystoMedix will sell, convey, transfer,
assign and deliver to Uroplasty (or to a subsidiary of Uroplasty, if so designated by Uroplasty,
referred to hereafter as the “Acquisition Subsidiary”), and Uroplasty (or its Acquisition
Subsidiary) will purchase from CystoMedix, the exclusive right, title and interest, free and clear
of all liens, security interests and encumbrances, in and to the following intellectual property
assets of CystoMedix (collectively, the “IP Assets”):

     (a) Patents and Patent Rights. All patents applied for, issued to or owned in whole
or in part by CystoMedix, or under which CystoMedix is licensed, which relate to the Products, all
inventions and discoveries described or contained therein, all licenses relating to any of the
foregoing and all income and royalties with respect to any licenses, all rights to sue for past,
present or future infringement thereof, all rights arising therefrom and pertaining thereto and all
reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof.
Without limitation, the IP Assets include U.S. Patent Nos. 6,493,588 and 5,711,314, U.S. Patent
Application Serial Nos. 10/195,197, 10/492,578 and 10/905,501 (and any patents that may issue with
respect thereto) and any other U.S. or foreign patent or patent applications owned or controlled by
CystoMedix (all together, the “Patent Rights”).

     (b) Trademarks and Tradenames. All state (including common law), federal and foreign
trademarks, service marks and trade names, URLs and domain names, and applications for registration
of such trademarks, service marks and trade names, URLs and domain names, which related to the
Products, all licenses relating to any of the foregoing and all income and royalties with respect
to any licenses, whether registered or unregistered and wherever registered, all rights to sue for
past, present or future infringement or unconsented use thereof, all rights arising therefrom and
pertaining thereto and all reissues, extensions and renewals thereof. Without limitation, the IP
Assets include the Trademarks, the tradename “CystoMedix” and the domain name “cystomedix.com” (all
together, the “Trademark Rights”).

-3-

 

     (c) Copyrights. All state, federal and foreign copyrights, copyright registrations,
and applications for copyright registrations, including, without limitation, derivative works,
which
relate to the Products, all licenses relating to any of the foregoing, all income and
royalties with respect to any licenses, all rights to sue for past, present or future infringement
or unconsented use thereof, and all extensions and renewals thereof and all documents, writings,
logos, artwork, tapes, disks, storage media, computer programs, computer databases, computer
program flow diagrams, source codes, object codes and all tangible property embodying or
incorporating the Copyrights (all together, the “Copyrights”).

     (d) Regulatory Assets. CystoMedix’s FDA 510(k) and foreign marketing clearances or
registrations for the Products (and the related rights, if any, that CystoMedix could claim to own
in any amended, modified or enhanced Products as developed and marketed by Uroplasty since entering
into the License Agreement), including, without limitation, all technical and design files related
to preclinical testing, design, clinical, manufacturing, marketing, distribution, labeling,
advertising, clinical adverse event experience (including investigational notes) and other
regulatory matters, and any and all worldwide regulatory agency/Notified Body/consultant
correspondence.

     (e) Product Design and Manufacturing Specifications. All product design and
manufacturing specifications, as amended, modified or enhanced from time to time, for the
manufacture of the Products (the “Products Design and Manufacturing Specifications”).

     2.2 The Retained Assets. All other assets of CystoMedix which are not specifically
listed as an IP Asset shall remain an asset of and owned by CystoMedix including but not limited to
the following (all together, the “Retained Assets”):

     (a) Cash and Accounts Receivable. Any and all cash and bank accounts and all
investments, investment accounts or other similar holdings, all accounts receivable and all credit
balances, reimbursements or rebates and any payments made or to be made by Uroplasty to CystoMedix
pursuant to the License Agreement through the Closing Date hereunder.

     (b) Tangible Assets. All of CystoMedix’s physical assets utilized by or useful to it
including, but not limited to, furniture, fixtures, equipment, machinery, hardware, office
equipment, tools, supplies, inventories and any other tangible personal property or assets owned by
CystoMedix.

     (c) Contracts and Agreements. All contracts and agreements of CystoMedix except
license agreements related to the IP Assets pursuant to Section 2.1(a) above.

     (d) Intangible Assets other than the IP Assets. All business plans, rights,
governmental permits, approvals or authorizations, CystoMedix’s telephone numbers and other
intangible property rights and interests applied for, issued to or owned in whole or in part by
CystoMedix, or under which CystoMedix is licensed, which is not an IP Asset.

     (e) Goodwill. CystoMedix as a going concern and all of its goodwill, if any.

-4-

 

     (f) Customers. Any and all of CystoMedix’s past and present customer lists, prospect
and prospect lists and relationships with customers and suppliers.

     (g) Business Records. All files, logs, records, books of account, financial records,
supplier files and lists, including telephone numbers, payroll and personnel records, marketing
data and reports, marketing information, brochures, photographs, advertising materials,
consultants’ reports, and other similar or related materials; provided the foregoing do not
contain a Trademark or Copyright or otherwise comprise the IP Assets.

     2.3 Assumption of Liabilities. Uroplasty (and its Acquisition Subsidiary, if
applicable) shall not assume and Uroplasty (and its Acquisition Subsidiary, if applicable) shall
not be liable for any of the obligations or liabilities of CystoMedix or for obligations related to
the IP Assets of any kind or nature other than obligations or liabilities arising under or related
to any of the IP Assets after the Closing Date which Uroplasty agrees to specifically assume at
Closing. All other obligations or liabilities of CystoMedix shall be the responsibility of
CystoMedix specifically including that certain loan in excess of $1,400,000 payable to Mr. J.
Stephen Schmidt, Chairman of CystoMedix or his affiliates (“Schmidt”), incurred by CystoMedix prior
to the date of the License Agreement (the “Bridge Loan”).

     2.4 Right of Inspection. From the date hereof and until Closing, CystoMedix will make
available at reasonable times CystoMedix’s books, records and other information as are requested by
Uroplasty for examination, and for the examination by its advisors and such other information
relating to the IP Assets as Uroplasty may reasonably request.

     2.5 Termination of License Agreement. Effective as of the Closing, all rights and
obligations of CystoMedix and Uroplasty under the License Agreement shall terminate in all
respects. As of the Closing Date, Uroplasty shall no longer be required to pay CystoMedix
royalties on sales of Products by Uroplasty as of and after the Closing Date and CystoMedix shall
have no rights to manufacture, sell, license or otherwise exploit the Products in any territory.
Accordingly, effective as of the Closing, CystoMedix and Uroplasty each release the other and its
respective officers, directors, stockholders, employees and agents from any claim, cause of action,
liability, damages or expenses, including attorneys’ fees, arising out of or with respect to the
License Agreement, whether known or unknown, matured or unmatured or fixed or contingent (it being
intended that this is a complete release as to the License Agreement by each of CystoMedix and
Uroplasty).

SECTION 3. PURCHASE CONSIDERATION

     3.1 Purchase Consideration; Manner of Payment.

     (a) As full payment for the transfer of the IP Assets under Section 2.1 by CystoMedix to
Uroplasty, Uroplasty agrees to pay CystoMedix the sum $4,900,000 plus 20,000 shares of
Uroplasty Common Stock (all together, the “Purchase Consideration”).

-5-

 

     (b) The $4,900,000 of Purchase Consideration shall also be payable in shares of Uroplasty
Common Stock. On the Closing Date, Uroplasty will issue to CystoMedix that number of shares of
Uroplasty’s Common Stock equal to $4,900,000 divided by the Share Price. The term “Share Price”
means the greater of (i) $3.00 per share or (ii) 15% in excess of the average of the closing price
of Uroplasty’s Common Stock, as quoted on the American Stock Exchange during the 20 trading days
prior to the Closing Date. For example, if the average 20 day trading closing price is $3.50, the
Share Price would be $3.50 x 1.15 or $4.025; and, if the average 20 day trading closing price is
$2.50, the Share Price would be $3.00 because $2.50 x 1.15 is $2.875, which is less than the $3.00
per share minimum. All share computations shall be rounded to the nearest whole share.

     (c) Sales and Use Taxes. CystoMedix shall pay any sales, use or other similar taxes
payable on account of the sale of the IP Assets to Uroplasty hereunder.

     3.2 Allocation of Purchase Consideration. The Purchase Consideration (also referred
to in this Agreement as the “Shares”) shall be allocated among the IP Assets in such manner as
Uroplasty shall reasonably specify in writing at Closing.

SECTION 4. CLOSING

     4.1 Closing. The closing (the “Closing”) of the transactions contemplated by this
Agreement shall take place at the offices of Messerli & Kramer P.A. at 10:00 a.m., local time, on
March 27, 2007 or at such other time and place and on such other date as Uroplasty and CystoMedix
shall agree (the “Closing Date”).

     4.2 Deliverables at Closing. The parties shall deliver the following instruments,
documents and property at the Closing to one another:

     (a) By Uroplasty. Uroplasty shall deliver an instruction letter to its stock transfer
agent, authorizing the issuances of the Shares and, no later than five Business Days after Closing,
Uroplasty shall deliver the stock certificate representing the Shares.

     (b) By CystoMedix and Schmidt. CystoMedix and Schmidt shall deliver the following
instruments, documents and property to Uroplasty at the Closing:

	 	(i)	 	a Bill of Sale substantially in a form acceptable to Uroplasty
as executed by CystoMedix;
	 
	 	(ii)	 	any and all assignments and other appropriate documents and
instruments in form necessary and reasonably acceptable to Uroplasty to
transfer and assign to Uroplasty the IP Assets specifically including a
Trademark Assignment and Patent Assignment in forms acceptable to Uroplasty to
be executed by CystoMedix or inventors of the IP Assets;

-6-

 

	 	(iii)	 	consents of third parties necessary to transfer the IP Assets
to Uroplasty unless waived in writing by Uroplasty;
	 
	 	(iv)	 	all physical files, documents, papers, notes, and certificates
whether in electronic form or hard copy form representing the IP Assets;
	 
	 	(v)	 	UCC-3 Termination Statements terminating liens, if any, on the
IP Assets;
	 
	 	(vi)	 	a one-year noncompetition agreement by CystoMedix and Schmidt
in form acceptable to Uroplasty precluding them from competing worldwide with
Uroplasty;
	 
	 	(vii)	 	a certificate of the President of CystoMedix certifying the
truth and accuracy of CystoMedix’s representations and warranties and
compliance with all of its covenants and agreements on and as of the Closing
Date; and
	 
	 	(viii)	 	resolutions of the Board of Directors and stockholders of CystoMedix
authorizing the transactions contemplated hereby.

     (c) Additional Matters. Each party agrees to execute and deliver such additional
instruments, documents and property, and to take such additional action, as may reasonably be
requested by another party hereto, or his, her or its counsel, in order to effectuate the
transactions contemplated by this Agreement. CystoMedix further agrees that it will cooperate with
and assist Uroplasty in acquiring the signatures of Jeffrey Williams and Hans van den Biggelaar,
prior to and after Closing, on any and all documents or instruments to effect the assignment of the
IP Assets.

     4.3 Conditions to Closing. The obligations of the parties to close hereunder are
subject to the satisfaction of the following conditions on or before the Closing Date (each of
which the applicable party agrees to timely perform and satisfy):

     (a) CystoMedix’s Obligation. The obligation of CystoMedix to consummate the
transactions contemplated by this Agreement is subject to satisfaction of the following
contingencies on or before the Closing Date:

	 	(i)	 	Uroplasty shall have performed, satisfied and complied with all
of its agreements, obligations and conditions required under this Agreement to
be performed or complied with by it prior to the Closing including delivering
of the instruction letter as specified in Section 4.2(a).
	 
	 	(ii)	 	The warranties and representations of Uroplasty made in this
Agreement are true as of the Closing Date as though made at that time and
Uroplasty shall
deliver a certificate as described above to that effect.

-7-

 

     (b) Uroplasty’s Obligation. The obligation of Uroplasty to consummate the
transactions contemplated by this Agreement is subject to satisfaction of the following
contingencies on or before the Closing Date:

	 	(i)	 	CystoMedix and Schmidt shall have performed, satisfied and
complied with all of their respective agreements, obligations and conditions
required under this Agreement to be performed or complied with by them prior to
or at the Closing including delivering all of the items specified in Section
4.2(b).
	 
	 	(ii)	 	The warranties and representations of CystoMedix made in this
Agreement are true and correct as of the Closing Date as though made at that
time and CystoMedix shall deliver a certificate as described above to that
effect.
	 
	 	(iii)	 	Jeffrey Williams, Hans van den Biggelaar and any other
inventors of any IP Assets shall have executed and delivered to CystoMedix all
assignments and other appropriate documents and instruments, including any
non-provisional patent applications and international patent applications, in
the form necessary and reasonably accepted to Uroplasty, to transfer, assign
and fully vest Uroplasty in the IP Assets.
	 
	 	(iv)	 	Uroplasty is satisfied that the IP Assets will be validly
transferred to and vested in Uroplasty upon delivery of the appropriate
assignment and other documents by CystoMedix at Closing.
	 
	 	(v)	 	The American Stock Exchange shall have approved Uroplasty’s
application for the listing of the Shares.
	 
	 	(vi)	 	The number of Shares required to be issued to CystoMedix on the
Closing Date shall not exceed twenty percent (20%) of Uroplasty’s total issued
and outstanding shares on the Business Day immediately prior to the Closing
Date.
	 
	 	(vii)	 	CystoMedix’s stockholders shall have approved this Agreement
and the transactions contemplated hereby.
	 
	 	(ix)	 	Uroplasty (in its sole discretion) shall have determined that,
since the Effective Date, there has been no material or adverse change in the
IP Assets or any purchase, sale, license or other disposition, or any agreement
or other arrangement for the purchase, sale, license or other disposition, of
any part of the IP Assets (including any patents, trademarks and copyrights)
except as provided in the Schedule of Changes (Schedule 5.8
hereto).

-8-

 

	 	(x)	 	Uroplasty shall have received certification from a certified
public accountant in a form satisfactory to it that the total amount due and
owing J. Stephen Schmidt on the Bridge Loan as of the Closing Date is at least
$1,400,000.

     4.4 No Shop. Until Closing or termination of this Agreement as provided below,
CystoMedix and Schmidt agree not to solicit, negotiate with or provide any information to any
person, firm or entity other than Uroplasty and its employees, accountants, attorneys and
representatives regarding any acquisition of the IP Assets whether by merger, stock sale or other
business combination.

     4.5 Termination Date. Notwithstanding any other provision of this Agreement, this
Agreement shall terminate and be of no effect (and each party hereto shall bear its own expenses of
any kind) if the Closing does not take place on or before April 20, 2007. Despite the foregoing,
if the Closing does not take place because a party hereto (the “Defaulting Party”) has not
delivered a required item under Section 4.2 to the other party (the “Non-Defaulting Party”) for the
Closing or satisfied a contingency to Closing under Section 4.3 (which is not waived in writing by
the Non-Defaulting Party), then, at the election in writing of the Non-Defaulting Party, the
Closing shall be postponed (but not beyond July 20, 2007) so that the Defaulting Party may remedy
its default. The Defaulting Party agrees that the Non-Defaulting Party may obtain an order
directing the Defaulting Party to comply with its obligations and to proceed with a Closing as
contemplated hereby.

SECTION 5. REPRESENTATIONS AND WARRANTIES OF SELLER

     As a material inducement to Uroplasty to enter into this Agreement and to consummate the
transactions contemplated hereby, CystoMedix hereby makes to Uroplasty each of the representations
and warranties set forth in this Section 5.

     5.1 Organization and Qualification; No Operations. CystoMedix is a corporation duly
organized, validly existing and in good standing under the laws of the State of Minnesota and has
full power and authority to own or lease its properties and to conduct its business in the manner
and in the places where such properties are owned or leased or as such business is currently
conducted. Except as described on the Schedule of Other Activities (Schedule 5.1),
CystoMedix is not and has not been since the date of the License Agreement engaged in the
manufacture, sale or distribution of the Products other than collecting royalties from Uroplasty
under the License Agreement. As of the Closing Date, CystoMedix’s business activities will consist
solely of holding the Shares and the Retained Assets.

-9-

 

     5.2 Authority. CystoMedix has full right, power and authority to enter into this
Agreement and each agreement, document and instrument to be executed and delivered by
CystoMedix pursuant to this Agreement and to carry out the transactions contemplated hereby
and thereby. The execution, delivery and performance of this Agreement and each such other
agreement, document and instrument by CystoMedix has been duly and validly authorized and approved
by all necessary action on the part of CystoMedix and no other action on the part of CystoMedix or
its stockholders is required in connection therewith. This Agreement and each agreement, document
and instrument to be executed and delivered by CystoMedix and Schmidt pursuant to this Agreement
constitutes, or when executed and delivered will constitute, the legal, valid and binding
obligation of CystoMedix and Schmidt, each enforceable in accordance with their respective terms,
except to the extent that enforcement is limited by bankruptcy, insolvency, moratorium,
conservatorship, receivership or similar laws of general application affecting creditors’ rights or
by the application by a court of equity principles. The execution, delivery and performance by
CystoMedix of this Agreement and each such agreement, document and instrument:

     (a) does not and will not violate any foreign, federal, state, local or other laws,
regulations or ordinances applicable to CystoMedix;

     (b) does not or will not violate any term or provision of the Articles or Bylaws of
CystoMedix; and

     (c) does not and will not result in a breach of, constitute or result in a default under,
accelerate any obligation under or give rise to a right of termination of, any indenture or loan or
credit agreement or any other agreement, contract, instrument, mortgage, lien, lease, permit,
authorization, order, writ, judgment, injunction, decree, determination or arbitration award to
which CystoMedix is a party or by which the IP Assets are bound or affected, or result in the
creation or imposition of any mortgage, pledge, lien, security interest or other charge or
encumbrance on any of the IP Assets.

     Except as obtained by CystoMedix prior to the Closing, no consent or waiver by, approval of,
or designation, declaration or filing with, any Person is required in connection with the
execution, delivery and performance by CystoMedix of this Agreement and each agreement, document
and instrument to be executed and delivered by CystoMedix pursuant to this Agreement.

     5.3 Title to IP Assets; Liens. CystoMedix has good and marketable title to the IP
Assets and none of the IP Assets is subject to any mortgage, pledge, lien, conditional sales
agreement, security interest, encumbrance or other charge except as specifically reflected in the
Schedule of Liens (Schedule 5.3). The IP Assets are the only assets used in or otherwise
necessary to the manufacture, sale, and distribution of the Products as currently manufactured and
distributed by Uroplasty under the License Agreement.

     5.4 Intellectual Property.

-10-

 

     (a) All Patent Rights, Trademarks and Copyrights (collectively, the “Intellectual Property”)
are listed in the Schedule of Intellectual Property (Schedule 5.4) attached hereto, which
Schedule indicates, with respect to each, the nature of CystoMedix’s interest therein and the
expiration date thereof or the date on which CystoMedix’s interest therein terminates. Except as
set forth on the Schedule of Intellectual Property, the Intellectual Property have been
duly registered in, filed in or issued by, as the case may be, the United States Patent and
Trademark Office, the United States Register of Copyrights or the corresponding offices of other
countries identified on said Schedule, and have been properly maintained and renewed in accordance
with all applicable provisions of law and administrative regulations in the United States and each
such country.

     (b) Except as set forth on the Schedule of Intellectual Property, the Intellectual
Property is owned exclusively by CystoMedix, free and clear of any attachments, liens, encumbrances
or adverse claims.

     (c) Except as set forth on the Schedule of Intellectual Property, there are no claims
or demands of any other person pertaining to the Intellectual Property and no proceedings have been
instituted, are pending or, to the Knowledge of CystoMedix, are threatened which challenge the
rights of CystoMedix in respect thereof and CystoMedix has no Knowledge of any facts which could be
the basis of any such claims. To the Knowledge of CystoMedix, there is no infringement of any of
the Intellectual Property by others nor is any of the Intellectual Property subject to any
outstanding order, decree, judgment, stipulation, settlement, lien, charge, encumbrance or
attachment. No claim or demand has been made and no proceeding has been filed or, to the Knowledge
of CystoMedix, is threatened to be filed charging CystoMedix with infringement of any patent, trade
name, trademark, service mark or copyright and CystoMedix does not know of any facts which could be
the basis of any such claims. To the Knowledge of CystoMedix, there are no royalties, honoraria,
fees or other payments payable by or on behalf of CystoMedix to any person with respect to any of
the Intellectual Property.

     5.5 Trade Secrets. CystoMedix owns or has the right to use, free and clear of any
claims or rights of others, all trade secrets, inventions, developments, manufacturing and secret
processes, and other information and know-how (if any) comprising the IP Assets. There are no
payments which are required to be made by or on behalf of CystoMedix for the use of such trade
secrets, inventions, developments, manufacturing and secret processes and know-how. To the
Knowledge of CystoMedix, none of the IP Assets contain, comprise or use any confidential
information, copyrighted materials, know-how or trade secrets of any third party.

     5.6 Litigation. Except as set forth on the Schedule of Litigation (Schedule
5.6 hereto), there are no suits, actions or administrative, arbitration or other proceedings or
governmental investigations pending or threatened against or relating to CystoMedix or the IP
Assets. Except as set forth on the Schedule of Litigation, CystoMedix is not otherwise
engaged as a party in any suit, action or administrative, arbitration or other proceeding.
CystoMedix has not entered into or been subject to any consent decree, compliance order or
administrative

-11-

 

order with respect to any of the IP Assets. CystoMedix has not received any request for
information, notice, demand letter, administrative inquiry or formal or informal complaint or claim
with respect to the IP Assets. Except as set forth on the Schedule of Litigation, there
are no existing or, to the Knowledge of CystoMedix, threatened product liability, warranty or other
similar claims, or any facts upon which a claim of such nature could be based, against CystoMedix
for services or products which are defective or fail to meet any service or product warranties.

     5.7 Taxes. CystoMedix has filed all Tax Returns that it was required to file. All
such Tax Returns were correct and complete in all respects. Except as set forth on the
Schedule of Tax Matters (Schedule 5.7 hereto), all Taxes owed by CystoMedix (whether or not
shown on any Tax Return) have been paid. There are no actual, pending or threatened liens,
encumbrances or charges against any of the IP Assets arising in connection with any failure (or
alleged failure) to pay any Tax.

     5.8 Absence of Certain Changes. Except as provided in the Schedule of Changes
(Schedule 5.8 hereto), since the date of the License Agreement, there has not been any change in
the IP Assets or any purchase, sale, license or other disposition, or any agreement or other
arrangement for the purchase, sale, license or other disposition, of any part of the IP Assets
(including any patents, trademarks and copyrights).

     5.9 Compliance with Laws. CystoMedix is not in material violation of any laws, rules
or regulations which apply to the conduct of CystoMedix’s business or properties which violation
has had or may be expected to have a material adverse effect on the IP Assets. There has never
been any citation, fine or penalty imposed, asserted or threatened against CystoMedix under any
foreign, federal, state, local or other law or regulation relating to medical device, employment,
immigration, occupational safety, zoning or environmental matters and CystoMedix is not aware of
any circumstances, occurrences or conditions likely to result in the imposition or assertion of
such a citation, fine or penalty, nor has CystoMedix received any notice to the effect that
CystoMedix is in violation of any such laws or regulations.

     5.10 Product Warranty. To the Knowledge of CystoMedix, each product manufactured,
sold, leased or delivered by it has been in conformity with all applicable contractual commitments
and all express and implied warranties.

     5.11 Product Liability. To the Knowledge of CystoMedix, CystoMedix has no liability
(and there is no basis for any present or future action, suit, proceeding, hearing, investigation,
charge, complaint, claim or demand against it giving rise to any liability) arising out of any
injury to individuals or property as a result of the ownership, possession or use of any product
manufactured, sold, leased or delivered or services rendered by it.

     5.12 Finders’ Fees. CystoMedix has not incurred and will not incur or become liable
for any broker’s commission or finder’s fee relating to or in connection with the transactions
contemplated by this Agreement.

-12-

 

     5.13 Authorizations. CystoMedix has obtained and is in material compliance with all
federal, foreign, state, provincial, municipal, local or other governmental consents,
certifications, licenses, permits, registrations, grants and other authorizations, including U.S.
Food and Drug Administration and foreign medical device directives (collectively the
“Authorizations” and individually an “Authorization”) which are necessary to permit it to conduct
its business as presently conducted and for which the failure to comply with has had or may be
expected to have a material adverse effect on the IP Assets. No proceeding is pending or, to the
Knowledge of CystoMedix, is threatened in which any Person or governmental authority is seeking to
revoke or deny the renewal of any Authorization.

     5.14 Hazardous Materials; Environmental Compliance; Disclosure of Environmental
Information. CystoMedix has never generated, used, stored or handled any Hazardous Materials
nor has it treated, stored, disposed of, spilled or released any Hazardous Materials at any site
presently or formerly owned, leased, operated or used by CystoMedix or shipped any Hazardous
Materials for treatment, storage or disposal at any other site or facilities. To the Knowledge of
CystoMedix, no other person has ever generated, used, handled, stored or disposed of any Hazardous
Materials at any site presently or formerly owned, leased, operated or used by CystoMedix, nor has
there been or is there threatened any release of any Hazardous Materials on or at any such site.
To the Knowledge of CystoMedix, CystoMedix does not presently own or lease, nor has it previously
owned or leased, any site on which underground storage tanks are or were located. No lien has been
imposed by any governmental agency on any property, facility, machinery, or equipment owned,
operated, leased or used by CystoMedix in connection with the presence of any Hazardous Materials.

     To the Knowledge of CystoMedix, CystoMedix has no liability under nor has it ever violated any
Environmental Law with respect to any property owned, operated, leased, or used by CystoMedix and
any facilities and operations thereon. In addition, any property owned, operated, leased, or used
by CystoMedix, and any facilities and operations thereon are presently in material compliance with
all applicable Environmental Laws. CystoMedix has not entered into or been subject to any consent
decree, compliance order or administrative order with respect to any environmental or health and
safety matter or received any request for information, notice, demand letter, administrative
inquiry, or formal or informal complaint or claim with respect to any environmental or health and
safety matter or any enforcement of any Environmental Law; and neither CystoMedix nor Schmidt have
any Knowledge that any of the above will be forthcoming.

     5.15 Completeness. The representations, warranties and statements contained in this
Agreement and in the certificates, exhibits and schedules delivered by CystoMedix to Uroplasty
pursuant to this Agreement, when taken together, do not and shall not contain any untrue statement
of a material fact, and do not and shall not omit to state a material fact required to be stated
therein or necessary in order to make such representations, warranties or statements not misleading
in light of the circumstances in which they were made.

-13-

 

     5.16 Certain Securities Law Matters. Through its officers and directors, CystoMedix
has such knowledge and experience in financial business matters that its is capable of evaluating
the merits and risks of an investment in Uroplasty Common Stock to be received pursuant to this
Agreement. CystoMedix acknowledges its access to Uroplasty’s annual, quarterly and periodic
reports filed with the U.S. Securities and Exchange Commission (the “SEC Reports”), and being
offered the opportunity to ask questions of, and receive answers from, Uroplasty’s officers with
respect to Uroplasty’s business and financial affairs. To the extent that CystoMedix has, in the
course of its investment or other discussions with Uroplasty, learned any confidential, proprietary
or trade secret information of Uroplasty, CystoMedix agrees to keep such information confidential
and to not use, or disclose to third parties (except to CystoMedix’s counsel and other advisors,
who are bound by this promise of confidentiality), any such information unless and until Uroplasty
publicly discloses such information. CystoMedix hereby acknowledges and agrees that the Uroplasty
Common Stock to be acquired pursuant to this Agreement is being acquired for its own account and
not for any other person, or with a view to distribution or sale thereof, and that such securities
have not been registered under the Act or applicable state securities or “Blue Sky” laws, and
therefore cannot be resold unless so registered or exempted therefrom. CystoMedix understands that
certificates representing the Uroplasty Common Stock will bear the following legend reflecting the
foregoing restrictions on transfer and the resale restriction described in Section 8.5 below:

“The shares of stock represented by this certificate have not been registered under the
Securities Act of 1933, as amended (the “Act”) or under any applicable state securities laws
(the “Laws”). The shares may not be sold, transferred, assigned, pledged or otherwise
disposed of at any time unless they are registered under such Act and laws or unless in the
opinion of legal counsel for the Company such disposition will not result in a violation of
such Act or any such Laws. In addition, the resale of the shares is restricted by the terms
of an Asset Purchase Agreement dated March 15, 2007, by and between Uroplasty, Inc. and
CystoMedix, Inc.”

SECTION 6. REPRESENTATIONS AND WARRANTIES OF UROPLASTY

     Uroplasty hereby makes to CystoMedix each of the representations and warranties set forth in
this Section 6 as follows:

     6.1 Organization and Good Standing. Uroplasty is a corporation duly organized,
validly existing and in good standing under the laws of the State of Minnesota with full corporate
power to conduct its business as now being conducted.

     6.2 Authority. Uroplasty has full right, power and authority to enter into this
Agreement and each agreement, document and instrument to be executed and delivered by it pursuant
to this Agreement and to carry out the transactions contemplated hereby and thereby. The
execution, delivery and performance of this Agreement and each such
other agreement, document and instrument by it has been duly and validly

-14-

 

authorized and approved by all
necessary action on its part and no other action on its part is required in connection therewith.
This Agreement and each agreement, document and instrument to be executed and delivered by
Uroplasty pursuant to this Agreement constitutes, or when executed and delivered will constitute,
the legal, valid and binding obligation of Uroplasty, enforceable in accordance with its respective
terms, except to the extent that enforcement is limited by bankruptcy, insolvency, moratorium,
conservatorship, receivership or similar laws of general application affecting creditors’ rights or
by the application by a court of equity principles. The execution, delivery and performance by
Uroplasty of this Agreement and each such agreement, document and instrument:

     (a) does not and will not violate any foreign, federal, state, local or other laws,
regulations or ordinances applicable to Uroplasty;

     (b) does not or will not violate any term or provision of the Articles of Incorporation or
Bylaws of Uroplasty; or

     (c) does not and will not result in a breach of, constitute or result in a default under,
accelerate any obligation under or give rise to a right of termination of, any indenture or loan or
credit agreement or any other agreement, contract, instrument, mortgage, lien, lease, permit,
authorization, order, writ, judgment, injunction, decree, determination or arbitration award to
which Uroplasty is a party or by which the property of Uroplasty is bound or affected, or result in
the creation or imposition of any mortgage, pledge, lien, security interest or other charge or
encumbrance on any of Uroplasty’s assets.

     No consent or waiver by, approval of, or designation, declaration or filing with, any Person
or authority (governmental or otherwise) is required in connection with the execution, delivery and
performance by Uroplasty of this Agreement and each agreement, document and instrument to be
executed and delivered by Uroplasty pursuant to this Agreement.

     6.3 Uroplasty Common Stock. The Uroplasty Common Stock being issued hereunder will be
(i) duly authorized, validly issued and outstanding, (ii) fully paid, non-assessable and free of
preemptive rights and (iii) except as otherwise provided by this Agreement, free and clear of any
and all pledges, claims, restrictions, charges, liens, security interests, encumbrances or other
interests of third parties of any nature whatsoever.

     6.3 SEC Reports; Financial Statements. Except as described on Schedule 6.3,
the Company has filed all SEC Reports required to be filed by it under the Act and the Exchange
Act, including pursuant to Section 13(a) or 15(d) thereof, for the twelve months preceding the date
hereof (or such shorter period as the Company was required by law to file such reports, forms or
other information). Unless corrected prior to the date of this Agreement in a subsequent SEC
Report, as of their respective dates, the SEC Reports complied in all material respects with the
requirements of the Act and the Exchange Act and the rules and regulations of the Commission
promulgated thereunder, and none of the SEC

-15-

 

Reports,
when filed (if applicable, as corrected prior to the date of this Agreement), contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they were made, not
misleading.

     6.4 Completeness. The representations, warranties and statements contained in this
Agreement and in the certificates, exhibits and schedules delivered by Uroplasty to CystoMedix
pursuant to this Agreement, when taken together, do not and shall not contain any untrue statement
of a material fact, and do not and shall not omit to state a material fact required to be stated
therein or necessary in order to make such representations, warranties or statements not misleading
in light of the circumstances in which they were made.

SECTION 7. INDEMNIFICATION

     7.1 Materiality; Survival. All representations, warranties, agreements, covenants
and obligations herein or in any schedule, certificate or financial statement delivered by any
party incident to the transactions contemplated hereby are material, shall be deemed to have been
relied upon by the parties and shall survive the Closing hereof.

     7.2 Indemnification.

     (a) CystoMedix agrees to defend, indemnify and hold Uroplasty and its respective subsidiaries
and affiliates and the persons serving as officers, directors, partners, employees or agents
thereof harmless from and against any claims, damages, liabilities, losses, fines, penalties,
costs, and expenses (including, without limitation, reasonable counsel fees and expenses as the
same are incurred; together referred to as “Losses”) of any kind or nature whatsoever which may be
sustained or suffered by any of them arising out of, based upon or in connection with any of the
following matters:

	 	(i)	 	a breach of any representation, warranty, agreement, covenant
or obligation made by CystoMedix in this Agreement or in any Schedule, Exhibit,
or certificate delivered hereunder or in connection herewith or by reason of
any claim, action or proceeding asserted or instituted growing out of any
matter or thing constituting a breach of such representations, warranties or
covenants;
	 
	 	(ii)	 	Fraud in connection with the making by CystoMedix of any
representation, warranty, covenant or obligation or an intentional
misrepresentation by CystoMedix of any representation, warranty, covenant or
obligation; and
	 
	 	(iii)	 	any return, rebate or other expense (including warranty,
installation, configuration or other service work) associated with products
shipped and/or installed, or services rendered, by CystoMedix prior to Closing.

-16-

 

     (b) Uroplasty shall give prompt written notice to CystoMedix of any claim, liability or
expense to which the indemnification obligations hereunder would apply. Such notice shall state
the information then available regarding the amount of such claim, liability or expense and shall
specify the provision or provisions of this Agreement under which the claim, liability or expense
is asserted. The failure to promptly notify CystoMedix as provided above shall not relieve
CystoMedix of any liability hereunder except to the extent that the rights of CystoMedix have been
materially and adversely prejudiced as a result of the failure to give, or the delay in giving,
such notice.

     (c) If such indemnification claim, liability or expense is the subject of litigation,
CystoMedix shall have the right to participate at its own expense in the defense of any such
litigation, or Uroplasty may authorize CystoMedix, if it so desires, to take over the defense of
such litigation so long as such defense is expeditious and is undertaken by counsel reasonably
acceptable to Uroplasty. Otherwise, Uroplasty will control the defense of such claim.

     (d) Upon resolution of the indemnification claim, whether by final judicial decision after all
periods for appeal have lapsed, settlement, arbitration decision or otherwise, Uroplasty shall give
CystoMedix written notice of the Losses incurred by Uroplasty with respect to the claim (the
“Uroplasty Final Notice”). Thereafter, CystoMedix shall have 30 days to give Uroplasty written
notice that it intends to dispute the amount of Uroplasty’s claimed Losses. Within 30 days after
receipt of said written notice, Uroplasty shall attempt to settle the dispute with CystoMedix. If
CystoMedix and Uroplasty do not reach settlement of Uroplasty’s claim within such 30 days, the
dispute may at any time thereafter be submitted by either party to arbitration in Minneapolis,
Minnesota, before three arbitrators, one of which is selected by CystoMedix, one of which is
selected by Uroplasty and the third of which is selected by the first two arbitrators. The
arbitration shall be conducted by the American Arbitration Association in accordance with the rules
and procedures of the American Arbitration Association then in effect. CystoMedix and Uroplasty
agree that the arbitrators’ award (which shall be agreed to unanimously by the arbitrators) shall
be final and binding upon them with respect to the dispute and may be entered in any court having
jurisdiction thereof. All costs of the arbitration (including the reasonable legal expenses of all
parties thereto) shall be borne by CystoMedix and/or Uroplasty in the amounts determined by the
arbitrators, which shall base such determination upon the relative merits of the respective
positions of the parties in the dispute. The judgment upon the award may be entered in any court
having jurisdiction thereof. There shall be added to the amount of any arbitration award interest
at the rate of 10% per annum on the amount required to be paid pursuant to such award. This
interest will be computed from the date payment would have been paid if not disputed by CystoMedix
to the date paid and the arbitrators shall include provisions therefor in any award rendered.

     Any claims as determined above in favor of Uroplasty first shall be resolved by cancellation
of Shares then held by CystoMedix. If the Uroplasty Final Notice is given and is not disputed by
CystoMedix, or if an arbitrators’ award on Uroplasty’s claim is granted, then the

-17-

 

shares to be canceled shall be valued at the average of the closing price per share for the
Uroplasty Common Stock as reported by the American Stock Exchange for the ten (10) trading days
ending on the trading day immediately prior to the date of the Uroplasty Final Notice (if not
disputed by CystoMedix) or arbitrators’ award (if disputed by CystoMedix), as the case may be. If
Uroplasty’s claim cannot be resolved with the number of shares of Uroplasty Common Stock then held
by CystoMedix, then CystoMedix shall within ten (10) business days after written demand, pay the
remaining claim amount to Uroplasty in cash.

     Despite the above provisions of this subsection (d), CystoMedix may resolve any claim by
paying cash to Uroplasty.

     (e) Notwithstanding anything else in this Section 7 to the contrary, no claim by Uroplasty
under Section 7 may be enforced against CystoMedix unless Uroplasty gives CystoMedix written notice
of such claim under Section 7.2(b) above within one (1) year from the Closing Date.

     (f) Notwithstanding anything to contrary in this Agreement, and except for the Shares referred
to in Section 8.5 below, CystoMedix shall not sell, distribute or otherwise dispose of or transfer
any Shares held by it until the later of (i) one (1) year after the Closing Date or (ii) resolution
of all Indemnifiable claims for which CystoMedix has received timely notice pursuant to this
Section 7.2.

SECTION 8. POST-CLOSING OBLIGATIONS.

     8.1 Registration Rights.

     (a) Request for Registration. If after the later of (i) one year following the
Closing or (ii) the date of final resolution of any Losses, CystoMedix gives Uroplasty written
notice that its board and stockholders have authorized a dissolution of CystoMedix, and if
Uroplasty is then eligible to use Form S-3 (or its then equivalent) as a registration statement
with the SEC, Uroplasty will use its commercially reasonable efforts to promptly file and obtain
effectiveness of a registration statement on Form S-3 (or its then equivalent) under the Act
covering the resale of the Shares to be distributed upon dissolution to CystoMedix’s stockholders.
If Uroplasty is not then eligible to use Form S-3 (or its then equivalent), and if within six (6)
months thereafter, Uroplasty determines to file a registration statement for its own account on
Form S-1 or SB-2 (or their then equivalents), Uroplasty will use its commercially reasonable
efforts to include the Shares for resale in such registration statement (the “Company Registration
Statement”). To the extent that the managing underwriter for the offering covered by the Company
Registration Statement determines in its judgment that it is impractical for marketing purposes to
include some or all of the Shares on the Company Registration Statement, Uroplasty will so reduce
the number of Shares included on the Company Registration Statement. In no event will Uroplasty
have any liability to CystoMedix or any of its stockholders if Uroplasty is unable to obtain
or maintain the effectiveness of any registration statement.

-18-

 

     (b) Expenses of Registration. With respect to each inclusion of Shares in a
registration statement pursuant to this Section 8.1, Uroplasty shall bear the following fees, costs
and expenses: all registration, filing and NASD fees, printing expenses, fees and disbursements of
counsel and accountants for Uroplasty and all legal fees and disbursements and other expenses of
complying with state securities or blue sky laws of any jurisdictions in which the securities to be
offered are to be registered or qualified. Fees and disbursements of counsel and accountants for
CystoMedix and its stockholders, underwriting discounts and commissions and transfer taxes for
CystoMedix and its stockholders and any other expenses incurred by CystoMedix or its stockholders
not expressly included above shall be borne by CystoMedix and its stockholders.

     (c) Registration Procedures. In the case of each registration effected by Uroplasty
pursuant to this Agreement, Uroplasty will keep CystoMedix advised in writing as to the initiation
of such registration and as to the completion thereof. Uroplasty will:

     (i) Prepare and file with the Commission a registration statement and such amendments
and supplements as may be necessary and use commercially reasonable efforts to cause such
registration statement to become and remain effective until the distribution described in
the registration statement has been completed or for two years, whichever first occurs; and

     (ii) Furnish to CystoMedix such reasonable number of copies of the registration
statement, preliminary prospectus, final prospectus and such other documents as such
underwriters may reasonably request in order to facilitate the public offering of such
securities.

     8.2 Registration Indemnification.

     (a) By Uroplasty. Uroplasty will indemnify CystoMedix, and CystoMedix’s officers and
directors, and each person controlling such CystoMedix within the meaning of Section 15 of the Act,
and each selling stockholder with respect to which registration has been effected pursuant to this
Agreement, against all expenses, claims, losses, damages or liabilities (or actions in respect
thereof), including any of the foregoing incurred in settlement of any litigation, commenced or
threatened, arising out of or based on any untrue statement (or alleged untrue statement) of a
material fact contained in any registration statement, prospectus, offering circular or other
document, or any amendment or supplement thereto, incident to any such registration, or based on
any omission (or alleged omission) to state therein a material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances in which they were made,
not misleading, or any violation by Uroplasty of the Act, the Exchange Act, state
securities laws or any rule or regulation promulgated under such laws applicable to Uroplasty
in connection with any such registration, and Uroplasty will reimburse each said persons for any
legal and any other expenses reasonably incurred in connection with investigating, preparing or
defending any such claim, loss, damage, liability or action, provided that Uroplasty will not be
liable in any such case (i) to the extent that any such claim, loss, damage, liability or expense
arises out of or is based on

-19-

 

any untrue
statement or omission or alleged untrue statement or
omission made in reliance upon and in conformity with written information furnished to Uroplasty by
or on behalf of any such persons and stated to be specifically for use therein or (ii) insofar as
the claim, loss, damage, liability or expense relates to any untrue statement or omission or
alleged untrue statement or omission made in any preliminary prospectus but eliminated or remedied
in the prospectus.

     (b) By CystoMedix and the Selling Stockholders. CystoMedix and the selling
stockholders will indemnify Uroplasty, each of its directors and officers, other holders of
Uroplasty’s securities covered by such registration statement, their officers and directors and
each person controlling such other holder within the meaning of Section 15 of the Act, each person
who controls Uroplasty within the meaning of Section 15 of the Act, against all claims, losses,
damages and liabilities (or actions in respect thereof) arising out of or based on any untrue
statement (or alleged untrue statement) of a material fact contained in any such registration
statement, prospectus, offering circular or other document, or any omission (or alleged omission)
to state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading, or any violation by CystoMedix or a selling stockholder, and each person
controlling it or them within the meaning of Section 15 of the Act, the Exchange Act, state
securities laws or any rule or regulation promulgated under such laws applicable to it, and will
reimburse Uroplasty, such other holders, such directors, officers, persons, underwriters or control
persons for any legal or any other expenses reasonably incurred, as such expenses are incurred, in
connection with investigating or defending any such claim, loss, damage, liability or action, but
in the case of Uroplasty or the other holders or their officers, directors or controlling persons,
only to the extent that such untrue statement (or alleged untrue statement) or omission (or alleged
omission) is made in such registration statement, prospectus, offering circular or other document
in reliance upon and in conformity with information furnished to Uroplasty by or on behalf of
CystoMedix or a selling stockholder.

     (c) Notice and Defense. Each party entitled to indemnification under this Section 8.2
(the “Indemnified Party”) shall give notice to the party required to provide indemnification (the
“Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to
which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any
such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party,
who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified
Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may
participate in such defense at such party’s expense, and provided further that the failure of any
Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its
obligations under this Agreement unless the failure to give such notice is materially prejudicial
to an Indemnifying Party’s ability to defend such action and provided
further, that the Indemnifying Party shall not assume the defense for matters as to which there is
a conflict of interest or there are separate and different defenses. No Indemnifying Party, in the
defense of any such claim or litigation, shall, except with the consent of each Indemnified Party
(whose consent shall not be unreasonably withheld), consent to entry of any judgment or enter into
any settlement which does not include as an unconditional term thereof the giving by the claimant
or plaintiff to such Indemnified

-20-

 

Party of a
release from all liability in respect to such claim or
litigation. Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with the
underwritten public offering are in conflict with the foregoing provisions, the provisions in the
underwriting agreement shall control.

     8.3 Information by CystoMedix and Selling Stockholders. CystoMedix and each selling
stockholder shall furnish to Uroplasty such information regarding CystoMedix, the Shares held by it
or them and the distribution proposed by CystoMedix as Uroplasty may request in writing and as
shall be required in connection with any registration referred to in this Agreement.

     8.4 Termination of Registration Rights. Despite anything else to the contrary, the
rights granted pursuant to Section 8 shall terminate upon the date CystoMedix or its stockholders
are able to immediately sell all Shares held by it or them under Rule 144 during any 90-day period.

     8.5 Private Resale Restriction. During the one year period commencing on the Closing
Date, CystoMedix (and its collective stockholders, to the extent that any Shares are distributed to
them) may privately resell no more than 150,000 Shares (limited to 15,000 Shares in the aggregate
for any particular calendar month); provided, that any resale of Shares must comply with the Act.
The balance of the Shares is subject to the restriction on resale or other transfer pursuant to
Section 7.2(f) above.

     8.6 Regulatory Bodies. Promptly after Closing, CystoMedix will notify the FDA and any
other worldwide regulatory bodies of its discontinuance of holding regulatory submissions or
establishment registrations.

SECTION 9. MISCELLANEOUS

     9.1 Fees and Expenses. Except as otherwise provided herein, each of the parties to
this Agreement will bear its own expenses in connection with the negotiation and consummation of
the transactions contemplated by this Agreement (it being understood that CystoMedix’s expenses
associated herewith will not be assumed by Uroplasty). All sales and transfer taxes, fees and
duties under applicable law (including all stock transfer taxes, fees and duties, if any) incurred
in connection with this Agreement or the transactions contemplated thereby will be borne and paid
by CystoMedix.

     9.2 Confidentiality. CystoMedix acknowledges that Uroplasty is a publicly traded
company and agree that it will treat the existence and terms of this Agreement and the transactions
contemplated hereby as strictly confidential and will not disclose them to any Person without the
prior written consent of Uroplasty or unless Uroplasty publicly discloses such information.

-21-

 

     9.3 Law Governing. This Agreement shall be governed by and construed in accordance
with the laws of the State of Minnesota without reference to the choice of law provisions thereof.
The parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the
courts of the State of Minnesota and of the United States of America located in the State of
Minnesota in connection with any suit, action or proceeding relating to this Agreement and the
transactions contemplated hereby (without, however, derogating from the exclusivity of the
arbitration procedures set forth in subparagraph 7.2(d) hereof) and agree not to commence any
action, suit or proceeding relating thereto except in such courts.

     9.4 Notices. All notices, requests, demands and other communications hereunder shall
be deemed to have been duly given on the date delivered if delivered by hand, three days after
being sent by certified or registered mail (postage prepaid and with return receipt requested), on
the date delivered if by overnight courier service, on the date delivered if by telecopy or other
written form of electronic confirmation:

	 	 	 
	To:     UROPLASTY:

	 	David B. Kaysen, President and Chief Executive Officer
	 

	 	5420 Feltl Road
	 

	 	Minnetonka, Minnesota 55343

(952) 426-6199 (telefax)
	 
	 	 
	With a copy to:

	 	Jeffrey C. Robbins, Esq.
	 

	 	Messerli & Kramer P.A.
	 

	 	150 South Fifth Street, Suite 1800
	 

	 	Minneapolis, Minnesota 55402
	 

	 	(612) 672-3777 (telefax)
	 
	 	 
	To:      CYSTOMEDIX:

	 	in care of Frank I. Harvey, Esq.
	 

	 	Larkin Hoffman Daly & Lindgren Ltd.
	 

	 	7900 Xerxes Avenue South, Suite 1500
	 

	 	Bloomington, Minnesota 55435
	 

	 	(952) 896-3333 (telefax)

or to such other address of which any party may notify the other parties as provided above.
Notices are effective upon receipt or, if mailed, five (5) business days after the placing thereof
in the United States mail in the manner provided above.

     9.5 Entire Agreement. This Agreement, including the Schedules and Exhibits referred
to herein, constitutes the entire agreement between the parties with respect to its subject matters
and supersedes all previous written or oral negotiations, commitments and writings; no promises,
representations, understandings, warranties and agreements have been made by any of the parties
hereto except as referred to herein or in such Schedules and Exhibits or in such other writings;
and all inducements to the making of this Agreement relied upon by all the parties hereto have been
expressed herein or in said Schedules or Exhibits or in such other writings.

-22-

 

     9.6 Assignability. This Agreement shall be binding upon, and shall be enforceable by
and inure to the benefit of, the parties named herein and their respective successors and assigns.

     9.7 Waivers; Severability. The failure of any of the parties to this Agreement to
require the performance of a term or obligation under this Agreement or the waiver by any of the
parties to this Agreement of any breach hereunder shall not prevent subsequent enforcement of such
term or obligation or be deemed a waiver of any subsequent breach hereunder. If any one or more of
the provisions of this Agreement are held to be invalid, illegal or unenforceable, the validity,
legality or enforceability of the remaining provisions of this Agreement will not be affected
thereby, and the parties will use all reasonable efforts to substitute for such invalid, illegal or
unenforceable provisions one or more valid, legal and enforceable provisions which, insofar as
practicable, implement the purposes and intents hereof. To the extent permitted by applicable law,
each party waives any provision of law which renders any provision of this Agreement invalid,
illegal or unenforceable in any respect.

     9.8 Specific Performance. Each of the parties acknowledges and agrees that the other
parties would be damaged irreparably in the event any of the provisions of this Agreement are not
performed in accordance with their specific terms or otherwise are breached. Accordingly, each of
the parties agrees that the other parties shall be entitled to an injunction or injunctions to
prevent breaches of the provisions of this Agreement and to enforce specifically this Agreement and
the terms and provisions hereof in any action instituted in any court of the United States or any
state thereof having jurisdiction over the Parties and the matters covered by this Agreement
(subject to the provisions set forth in Section 7.2), in addition to any other remedy to which they
may be entitled, at law or in equity.

     9.9 Counterparts. This Agreement may be executed by facsimile and in any number of
counterparts, each of which shall be deemed an original and all of which shall constitute one and
the same agreement.

     9.10 Amendments. This Agreement may not be amended or modified, nor may compliance
with any condition or covenant set forth herein be waived, except by a writing duly and validly
executed by each party hereto, or in the case of a waiver, the party waiving compliance.

-23-

 

[SIGNATURE PAGE TO ASSET PURCHASE AGREEMENT DATED MARCH 15, 2007]

IN WITNESS WHEREOF, the undersigned have hereto affixed their signatures.

	 	 	 	 	 	 	 	 	 	 	 
	Uroplasty, Inc.	 	 	 	CystoMedix, Inc.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By

	 	 	 	 	 	By	 	 	 	 
	 

	 	 

David B. Kaysen, President and
	 	 	 	 	 	 

Jeffrey M. Williams, President and
	 	 
	 

	 	Chief Executive Officer
	 	 	 	 	 	Chief Executive Officer	 	 

-24-

 

Schedule 5.1

Other Activities

-25-

 

Schedule 5.3

Liens

-26-

 

Schedule 5.4

Intellectual Property

-27-

 

Schedule 5.6

Litigation

-28-

 

Schedule 5.7

Tax Matters

-29-

 

Schedule 5.8

Changes

-30-

 

CystoMedix, Inc.

1887 Station Parkway N.W., Building #7

Andover, Minnesota 55304

March ____, 2006

 

 

 

Dear                     :

     As you are aware, in April 2005, we entered into a five-year Exclusive Manufacturing and
Distribution Agreement with Uroplasty, Inc. At the time, we also granted Uroplasty an option and a
right of first refusal to acquire our assets.

     Based upon our recent negotiations, Uroplasty has agreed to purchase our intellectual property
assets now, but not our business or goodwill, solely in exchange for Uroplasty Common Stock. As a
condition of this revised purchase agreement (a copy of which we are providing to you subject to
your obligation of confidentiality below), Uroplasty requires that the holders of a majority of our
outstanding Common Stock consent to the agreement. By your signature below, you hereby grant this
consent. You also hereby appoint J. Stephen Schmidt as your attorney-in-fact (with full power of
substitution) to vote all of your shares at any meeting of CystoMedix stockholders held at any time
in favor of approving the purchase agreement and the transactions contemplated by it, or to execute
written consents on your behalf in lieu of any such meeting. Because of the benefit that
CystoMedix, and therefore you as a stockholder, will receive in connection with the Uroplasty
purchase agreement, this proxy and power of attorney is coupled with an interest and is
irrevocable. If for any reason your proxy and power of attorney is not effective, your signature
constitutes your separate agreement with Mr. Schmidt to vote all of your shares at any meeting of
CystoMedix stockholders held at any time in favor of approving the purchase agreement and the
transactions contemplated by it.

     Until Uroplasty makes a publicly discloses the purchase agreement, you also agree to keep
confidential its existence and terms. You further agree that you will not, directly or indirectly,
purchase or sell (whether in a short sale transaction or otherwise) any of Uroplasty’s Common Stock
(or options, warrants or other rights to purchase or acquire Uroplasty Common Stock) until the day
following the date Uroplasty issues a press release announcing the terms and conditions of the
purchase agreement.

     If this letter is acceptable, please so indicate by your signature below.

	 	 	 	 	 	 	 	 	 
	Very truly yours,	 	 	 	Agreed to and accepted:
	 
	 	 	 	 	 	 	 	 
	CystoMedix, Inc.	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By
	 	 	 	 	 	 	 	 
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Its

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]